Board of Directors

Barry Hoeven

Barry Hoeven

Barry Hoeven is an avid businessman and real estate entrepreneur, who was diagnosed with kidney cancer in 1998.  After diagnosis, the Hoevens soon realized the lack of funding going into kidney cancer research and other orphan cancers.  As a result, few medical breakthroughs had been made. The new understanding was the driving force behind the decision to form Kure It and the effort to fund innovative research.  Since then, Barry and his family have been fighting an ongoing battle with cancer, both personally and on the research front.

Kure It has raised more than $1,000,000 since 2007, which has gone directly to cancer researchers.  Contributions from Kure It have helped oncologists study new treatments and the basic biology behind these treatments, in hopes of finding the cure to kidney and other orphan cancers.

In addition to creating Kure It, Hoeven is the President of Westport Properties, Inc. and US Storage Centers, Inc.  Westport Properties is a real estate development and management company that owns, through affiliated entities, or manages self-storage properties under the brand name US Storage Centers.  There are approximately 45 self-storage and other commercial properties in six states, representing three million square feet.

Barry Hoeven has over 30 years of real estate experience, with a heavy emphasis in all aspects of self-storage and business park development.  His prior work experience included various senior level positions with Public Storage, the Irvine Company and the Colliers-Seeley Company.

On top of the work he does with his companies, Hoeven is involved with other organizations in Southern California, including those that support children and career development.

He is a University of Southern California graduate, having received a Business Degree, with an emphasis in finance and marketing, and an MBA in the Entrepreneurial program at the institution.

He and his wife Cinda have three adult children and reside in Newport Beach, CA.

Dr. Robert A. Figlin

Robert A. Figlin, M.D., F.A.C.P.

Robert A. Figlin, M.D., F.A.C.P., is the Director of the Division of Hematology/Oncology in the Department of Medicine and the Associate Director for Academic Program Development for the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin focuses his research on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai, which aims to understand the biology of kidney cancer and translate that knowledge into new treatments. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai’s tradition of compassionate patient care

Prior to joining Cedars-Sinai, Dr. Figlin served as the interim Cancer Center Director and Chair of the Department of Medical Oncology and Therapeutics Research at the City of Hope Comprehensive Cancer Center.  Prior to that, Dr. Figlin served as the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA.  Dr. Figlin joined the UCLA faculty in 1982 as Assistant Professor of Medicine in the Division of Hematology/Oncology and was appointed Co-Director of the Jonsson Comprehensive Cancer Center’s Oncology Program in 1993. He also held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Development Therapeutics within the Cancer Center.

Dr. Figlin serves as editor for the Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, theJournal of Clinical Oncology, New England Journal of Medicine, Lancet, and the Journal of Urology, among others. Dr. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology the David Geffen School of Medicine.

Robert M. Campbell

Robert M. Campbell

It is with great sadness that we announce the passing of Kure It Board member Bob Campbell. 

Bob was a well-loved and highly respected businessman, who was known as much for his philanthropic efforts as for his business success. 

His input and expertise will be missed by our organization, and we offer our condolences to his family and all those who knew and loved Bob.